Rezolute Inc is primarily active in the pharmaceutical industry.

The main competitors of Rezolute Inc in the market include companies such as Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., and Pfizer Inc. These companies also operate in the pharmaceutical and biotechnology industry, focusing on the development and commercialization of innovative therapies. Rezolute Inc competes with these industry leaders by offering its unique portfolio of products and striving to provide effective solutions to patients in need.

Rezolute Inc is a pharmaceutical company founded in 2010. It focuses on the development of therapeutics for chronic diseases like diabetes and rare genetic disorders. Rezolute is committed to providing innovative and effective solutions to improve patient outcomes in these areas. With a dedicated team of experts, the company utilizes cutting-edge technologies to advance its pipeline of drug candidates. Rezolute's history is marked by strategic collaborations and partnerships with leading industry players, reinforcing its position as a promising player in the biopharmaceutical sector. Through its continuous efforts, Rezolute aims to make a significant impact on the lives of patients worldwide.

Rezolute Inc has achieved several significant milestones in its operations. One notable achievement is the successful completion of its Phase 1 clinical trial for its lead candidate, RZ358, in patients with congenital hyperinsulinism (CHI). This milestone demonstrated the safety and tolerability of RZ358 and its potential to treat CHI, a rare genetic disorder. Additionally, the company has obtained orphan drug designation from the FDA for RZ358, providing it with exclusive market rights and potential financial incentives. Rezolute Inc has also entered into strategic partnerships and collaborations with renowned institutions, accelerating the development and commercialization of its innovative therapeutics.

Rezolute Inc primarily operates in the United States.

Rezolute Inc represents values such as innovation, dedication, and integrity. The company focuses on developing novel therapies and solutions for patients with chronic and rare diseases. Rezolute Inc's corporate philosophy is centered around prioritizing patient well-being and improving their quality of life through cutting-edge research and development. With a strong emphasis on scientific excellence and collaboration, Rezolute Inc strives to provide groundbreaking medical solutions that address unmet medical needs.

Analysts currently set an average price target of 6,38 USD for the Rezolute stock (median: 5,10 USD), implying +35,1 % versus the latest price. The consensus is based on 16 analyst ratings.

Rezolute Analyytikkojen kursstavoitteet 2026

16 analysts currently rate the Rezolute stock: 11 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Rezolute to generate revenue of 385 714,00 USD and earnings per share of −0,51 USD.

Rezolute Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Rezolute share trades at 4,10 EUR (4,72 USD).

The Rezolute share (RZLT) is listed on 1 stock exchanges, including: NASDAQ (RZLT).

The company Rezolute Inc is a US-based biopharmaceutical company that focuses on the discovery and development of new therapeutics for rare endocrine and metabolic disorders. The business model of Rezolute Inc is based on deep biological and medical expertise, high standards for clinical development, and efficient project management to bring new biopharmaceutical products to the market. Rezolute Inc has two main divisions that focus on the discovery and development of drugs suitable for rare endocrine and metabolic disorders. The first division is engaged in the development of peptide and monoclonal antibody drugs for the treatment of congenital hyperinsulinism, diabetes mellitus, and other insulin-resistant diseases. The second division focuses on the discovery and development of drugs for the treatment of rare metabolic diseases such as lysosomal storage diseases, cellular metabolic disorders, and mitochondrial diseases. Rezolute Inc aims to improve the quality of life for patients with rare diseases. To achieve this, the company develops new compounds and products that provide effective and safe therapies for these diseases. Rezolute Inc utilizes a combination of traditional and innovative technologies to maximize the efficacy and safety of new therapeutics. The company works closely with regulatory authorities to obtain approval for new drugs and make them accessible worldwide. Rezolute Inc has several products in the pipeline that are expected to be released soon. These include RZ358, an oral drug for the treatment of congenital hyperinsulinism, and RZ402, an oral drug for the treatment of metabolic disorders. Additionally, the company is working on the clinical development of RZ358 for the treatment of diabetes mellitus, a chronic metabolic disorder that affects millions of people worldwide. In addition to its development activities, Rezolute Inc conducts extensive research and development to identify and develop innovative therapeutic technologies. The company has formed partnerships with academic research institutions, hospitals, and pharmaceutical companies around the world to expand its knowledge and expertise in this area. In summary, Rezolute Inc is a biopharmaceutical company dedicated to the development of therapies for rare endocrine and metabolic disorders. The company uses a combination of traditional and innovative technologies and has an extensive product pipeline tailored to the needs of patients. Rezolute Inc works closely with regulatory authorities to obtain approval for new drugs and make them accessible worldwide.

odotettu liikevaihto Rezolute on 385 714,00 USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Rezolute on −53,19 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Rezolute:n hinta-voitto-suhde (P/E) on tällä hetkellä −9,20. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Rezolute-osakkeen arvostusta.

Rezolute:n hinta-myynti-suhde (P/S) on tällä hetkellä 1 268,82. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Rezolute-osakkeen arvostuskennuslukuna.

Rezolute:n Eulpool-laatuscore on 2/10.

Rezolute:n ISIN on US76200L3096. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Rezolute:n ticker on RZLT. Tämä pörssinoteeraus käytetään Rezolute-osakkeiden kauppaan pörssissä.

Rezolute maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Rezolute kuuluu sektoriin 'Terveydenhuolto'.

Rezolute:n osingot jaetaan valuutassa USD.